- Home
- IMAB vs NGNE Comparison
IMAB vs NGNE Comparison
Compare IMAB & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- NGNE
- Stock Information
- Founded
- IMAB 2014
- NGNE 2003
- Country
- IMAB United States
- NGNE United States
- Employees
- IMAB N/A
- NGNE N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- NGNE Health Care
- Exchange
- IMAB Nasdaq
- NGNE Nasdaq
- Market Cap
- IMAB 384.6M
- NGNE 325.3M
- IPO Year
- IMAB 2020
- NGNE N/A
- Fundamental
- Price
- IMAB $3.69
- NGNE $17.71
- Analyst Decision
- IMAB Strong Buy
- NGNE Strong Buy
- Analyst Count
- IMAB 5
- NGNE 7
- Target Price
- IMAB $6.80
- NGNE $41.86
- AVG Volume (30 Days)
- IMAB 1.7M
- NGNE 133.6K
- Earning Date
- IMAB 11-02-2025
- NGNE 11-14-2025
- Dividend Yield
- IMAB N/A
- NGNE N/A
- EPS Growth
- IMAB N/A
- NGNE N/A
- EPS
- IMAB N/A
- NGNE N/A
- Revenue
- IMAB N/A
- NGNE N/A
- Revenue This Year
- IMAB N/A
- NGNE N/A
- Revenue Next Year
- IMAB N/A
- NGNE N/A
- P/E Ratio
- IMAB N/A
- NGNE N/A
- Revenue Growth
- IMAB N/A
- NGNE N/A
- 52 Week Low
- IMAB $0.60
- NGNE $6.88
- 52 Week High
- IMAB $5.90
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- IMAB 45.33
- NGNE 38.90
- Support Level
- IMAB $3.20
- NGNE $17.13
- Resistance Level
- IMAB $4.64
- NGNE $20.72
- Average True Range (ATR)
- IMAB 0.41
- NGNE 1.29
- MACD
- IMAB -0.17
- NGNE -0.18
- Stochastic Oscillator
- IMAB 29.88
- NGNE 16.20
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.